by
Keith Loria, Reporter | February 18, 2009
There have been some noteworthy findings in a new multicenter clinical trial that was released in February, which compared the sensitivity of traditional breast CA detection technologies (MRI, sonography, and mammography) versus the newest one called the Breast Specific Gamma Imaging (BSGI).
Dilon Technologies in Newport News, VA has commercialized BSGI, which relies on a pharmaceutical tracing agent that emits gamma radiation after it is injected and taken up by all cells of the body. It is thought to work by detecting the increased metabolic activity of cancerous cells as compared to surrounding tissues.
Their recent study showed that its diagnostic modality is independent of tissue density and can discover very early stage cancers, hence the firm is hoping that one day BCGI will become a standard adjunctive molecular breast imaging technique to mammography. The results of the latest trial show that company's Dilon 6800 Gamma Camera and the diagnostic system seem to be as good as the other modalities for detecting small tumors within breasts.
Ad Statistics
Times Displayed: 45539
Times Visited: 1299 Ampronix, a Top Master Distributor for Sony Medical, provides Sales, Service & Exchanges for Sony Surgical Displays, Printers, & More. Rely on Us for Expert Support Tailored to Your Needs. Email info@ampronix.com or Call 949-273-8000 for Premier Pricing.
"Breast imaging centers across the country and around the world are using BSGI to pave the way to effective diagnosis of breast cancer," Bob Moussa, President and CEO of Dilon Technologies, said. "More than 50,000 patients have been imaged with BSGI. As we move forward into 2009, we will continue the momentum with the help of physicians worldwide."
The study looked at 26 women ranging in age from 46 to 82 with a total of 28 biopsy-proven invasive lobular carcinomas. Mammograms were negative in six of 28 (21%), yielding a sensitivity of 79%. In the 25 patients who underwent sonography, 17 had focal hypoechoic areas, yielding a sensitivity of 68%. In the 12 patients who underwent MRI, the sensitivity was 83%. BSGI had a sensitivity of 93%.
These findings suggest that BSGI has the highest sensitivity for the detection of invasive lobular carcinoma with a sensitivity of 93%, whereas mammography, sonography, and MRI showed sensitivities of 79%, 68%, and 83%, respectively. BSGI is an effective technique that should be used to evaluate patients with suspected cancer and has a promising role in the diagnosis of invasive lobular carcinoma.
